TCL Archive NSABP Trial Finds Raloxifene Equivalent To Tamoxifen For Cancer Risk Reduction April 28, 2006Vol.29 No.4
TCL Archive Celebrex Studies Show Polyp Reduction, Point To Challenges In Biomarker Validation April 28, 2006Vol.29 No.4
TCL Archive Advocacy Groups Consider Pros And Cons Of Forming Co-Pay Foundations. April 28, 2006Vol.32 No.16
TCL Archive A Message From NCI: “We Deeply Regret The Need To Eliminate This Program.” AP4 Applicants And Corporate Partners Spent Years, Money, Before NCI Pulled The Plug On Novel Public-Private Partnerships. Von Eschenbach Called AP4 “A New Paradigm” For Drug Development. NCI Executive Committee “Prioritized” Programs. April 21, 2006Vol.32 No.15
TCL Archive Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction. April 21, 2006Vol.32 No.15
TCL Archive Remarks on HPV Vaccines, SPORE Funds Create Controversy for NCI’s John Niederhuber. April 14, 2006Vol.32 No.14
